Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Capsaicin extracted from chilies is used in pepper sprays and some tear gas formulations as a chemical irritant, for use as less-lethal weapons for control of unruly individuals or crowds. Such products have considerable potential for misuse, and may cause injury or death. In Africa and Asia, elephants nightly destroy crops and endanger people. Chilis are effective at keeping elephants away, as capsaicin irritates their large and sensitive olfactory and nasal system. Farmers can plant a few rows of the fruit around valuable crops; or they may burn chili dung bombs, bricks of dung and chili, creating a noxious smoke. Birds do not have the same sensitivity to capsaicin as mammals, as they lack a specific pain receptor. Some species in the chili peppers' natural range eat the fruits, possibly dispersing the seeds.
=== Detection in body fluids === Modafinil and/or its major metabolite, modafinil acid, may be quantified in Plasma, serum, or urine to monitor dosage in those receiving modafinil therapeutically, to confirm a diagnosis of poisoning in hospitalized patients, or to assist in the forensic investigation of a vehicular traffic violation. Instrumental techniques involving gas or liquid chromatography are usually employed for these purposes. In 2011, modafinil was not tested for by common drug screens (except for anti-doping screens) and is unlikely to cause false positives for other chemically unrelated drugs such as substituted amphetamines. Reagent testing can screen for the presence of modafinil in samples.
=== Orthogonal sets in model organisms === The orthogonal pairs of synthetase and tRNA that work for one organism may not work for another, as the synthetase may mis-aminoacylate endogenous tRNAs or the tRNA be mis-aminoacylated itself by an endogenous synthetase. As a result, the sets created to date differ between organisms.
Sources: en.wikipedia.org
== 1980 incident == On the evening of December 21, 1980, while celebrating Christmas with her family at their mansion, Clarendon Court, in Newport, Rhode Island, she again displayed confusion and lack of coordination. She was put to bed by her family, but in the morning she was discovered unconscious on the bathroom floor. She was taken to the hospital where it became clear that this time she had suffered severe enough brain injury to produce a persistent vegetative state. Although clinical features resembled a drug overdose, some of the laboratory evidence suggested hypoglycemia. The Court of Appeal ordered disclosure of the notes taken by the Auersperg children's attorney. These showed that Claus von Bülow did not want to terminate life support, as had been alleged. Because of the increased marital tensions between Claus and Sunny von Bülow in the fall of 1980, her children were suspicious that her brain injury was the result of foul play by him. Her two eldest children persuaded Richard H. Kuh, the former New York County District Attorney, to investigate the possibility Claus von Bülow had attempted the murder of their mother. After the gathering of evidence, Rhode Island prosecutors presented the case to a grand jury who returned an indictment, and in July 1981, he was charged with two counts of attempted murder.
In 1943, Glaxo was responsible for 2,570 million of the 3,500 million Oxford units produced in the UK. Glaxo opened a third factory at Watford in February 1944 and a fourth at Stratford, London, in January 1945. The company was responsible for 80 per cent of the UK's output up to June 1944. In 1944 the Ministry of Supply arranged for the Commercial Solvents Company to install the first deep submergence plant at Speke, and it asked Glaxo to build one too. This new Glaxo plant opened at Barnard Castle in January 1946 and produced more penicillin over the next nine months than its surface plants had produced in all of 1945. The surface plants were all closed in 1946. Penicillin production in the UK increased from 25 million units per week in March 1943 to 30 billion per week in 1946.
== History == Ember was founded in 2001 by Andrew Wheeler and Robert Poor. Both were students at MIT when they founded Ember with $3 million in seed funding led by Polaris Venture Partners with DFJ New England, Stata Venture Partners, and Bob Metcalfe. The company began by making mesh networking software for other companies' microchips and has since evolved to manufacturing Zigbee compliant chips itself. In 2003, Ember released its first chip, the EM2420, which was fully compliant with IEEE 802.15.4-2003 standards. Since then, Ember has released the EM260 Zigbee network co-processor and the EM250, Zigbee system-on-chip (SoC), and EmberZNet Zigbee Software in 2005. In 2007, the EmberZNet PRO was launched to provide software that supports the Zigbee PRO Feature Set. The Smart Energy Suite and new versions of Zigbee Development Tools came out in 2008. In 2009, Ember released its third generation chips, the EM300 series. In May 2012, Ember was acquired by Silicon Labs.
Sources: en.wikipedia.org
=== Fetal blood supply === In the growing fetus, a major source of blood to the liver is the umbilical vein, which supplies nutrients to the growing fetus. The umbilical vein enters the abdomen at the umbilicus and passes upward along the free margin of the falciform ligament of the liver to the inferior surface of the liver. There, it joins with the left branch of the portal vein. The ductus venosus carries blood from the left portal vein to the left hepatic vein and then to the inferior vena cava, allowing placental blood to bypass the liver. In the fetus, the liver does not perform the normal digestive processes and filtration of the infant liver because nutrients are received directly from the mother via the placenta. The fetal liver releases some blood stem cells that migrate to the fetal thymus, creating the T cells (or T lymphocytes). After birth, the formation of blood stem cells shifts to the red bone marrow. After 2–5 days, the umbilical vein and ductus venosus are obliterated; the former becomes the round ligament of liver and the latter becomes the ligamentum venosum. In the disorders of cirrhosis and portal hypertension, the umbilical vein can open up again. Unlike eutherian mammals, in marsupials the liver remains haematopoietic well after birth.
=== Regulation === In order to ensure proper functioning, Wnt signaling is constantly regulated at several points along its signaling pathways. For example, Wnt proteins are palmitoylated. The protein porcupine mediates this process, which means that it helps regulate when the Wnt ligand is secreted by determining when it is fully formed. Secretion is further controlled with proteins such as GPR177 (wntless) and evenness interrupted and complexes such as the retromer complex. Upon secretion, the ligand can be prevented from reaching its receptor through the binding of proteins such as the stabilizers Dally and glypican 3 (GPC3), which inhibit diffusion. In cancer cells, both the heparan sulfate chains and the core protein of GPC3 are involved in regulating Wnt binding and activation for cell proliferation. Wnt recognizes a heparan sulfate structure on GPC3, which contains IdoA2S and GlcNS6S, and the 3-O-sulfation in GlcNS6S3S enhances the binding of Wnt to the heparan sulfate glypican. A cysteine-rich domain at the N-lobe of GPC3 has been identified to form a Wnt-binding hydrophobic groove including phenylalanine-41 that interacts with Wnt. Blocking the Wnt binding domain using a nanobody called HN3 can inhibit Wnt activation. At the Fz receptor, the binding of proteins other than Wnt can antagonize signaling. Specific antagonists include Dickkopf (Dkk), Wnt inhibitory factor 1 (WIF-1), secreted Frizzled-related proteins (SFRP), Cerberus, Frzb, Wise, SOST, and Naked cuticle. These constitute inhibitors of Wnt signaling. However, other molecules also act as activators.
In December 2008, the 3d BCT deployed to Baghdad, Iraq and redeployed to Ft. Bragg in November 2009. In August 2009, 1st BCT deployed once again to Iraq and redeployed late July 2010. During the months of August and September 2009, 4th BCT deployed again to Afghanistan and returned in August 2010 having lost 38 soldiers. In May 2011 1–505 (Task Force 1 Panther) deployed to Afghanistan in support of Operation Enduring Freedom. Dispersed throughout the country, 1st battalion was attached to various Special Operations elements. 1st battalion redeployed to Fort Bragg, NC in February 2012 having lost two paratroopers. The 2d Brigade deployed to the Al Anbar Governorate in Iraq in May 2011, for the last time, as part of Operation New Dawn. Its mission was to advise, train and assist the Iraqi Armed Forces and Ministry of the Interior forces, as part of the withdrawal of United States Forces – Iraq. Elements of 2d Brigade were among the last US combat units to withdraw from Baghdad. The brigade suffered the loss of the last American service member in Iraq, SPC. David E. Hickman, on 14 November 2011. They were part of the long convoy of equipment and troops who exited Iraq into Kuwait as OIF came to an end.
Environmental racism – Environmental injustice that occurs within a racialized context List of industrial disasters Ludhiana gas leak – Fatal incident in Punjab, India System accident – Unanticipated interaction of multiple failures in a complex system
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.